Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group

Camillo Porta, C. Porta, A. Ardizzoni, G. Gaudino, M. Maio, L. Mutti, C. Pinto, S. Porru, R. Puntoni, G. Tassi, M. Tognon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years. Indeed, an actual "epidemic" is expected in the next 20 years, with over 1300 new cases a y ear till 2020 at least. Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor. For all the above reasons, translational research is the key to success; indeed, ever increasing knowledge of the molecular mechanisms underlying MMe pathogenesis could lead (and is actually leading) to new, hopefully more active, treatment options. To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe). The aim of this report is to summarize the most significant advances in the different disciplines applied to MMe presented and discussed during the IMIG meeting and how these advances will be changing the perspective of patients with MMe.

Original languageEnglish
Pages (from-to)360-369
Number of pages10
JournalMedicina del Lavoro
Volume96
Issue number4
Publication statusPublished - 2005

Fingerprint

Public Opinion
Mesothelioma
Technology
Pharmaceutical Preparations
Group Processes
Translational Medical Research
Group Psychotherapy
Malignant Mesothelioma
Italy
Ear
Therapeutics
Research Personnel
Incidence

Keywords

  • GIMe
  • IMIG
  • Malignant mesothelioma

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Malignant mesothelioma in 2004 : How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group. / Porta, Camillo; Porta, C.; Ardizzoni, A.; Gaudino, G.; Maio, M.; Mutti, L.; Pinto, C.; Porru, S.; Puntoni, R.; Tassi, G.; Tognon, M.

In: Medicina del Lavoro, Vol. 96, No. 4, 2005, p. 360-369.

Research output: Contribution to journalArticle

Porta, Camillo ; Porta, C. ; Ardizzoni, A. ; Gaudino, G. ; Maio, M. ; Mutti, L. ; Pinto, C. ; Porru, S. ; Puntoni, R. ; Tassi, G. ; Tognon, M. / Malignant mesothelioma in 2004 : How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group. In: Medicina del Lavoro. 2005 ; Vol. 96, No. 4. pp. 360-369.
@article{e564c1f4a7c34fcba06741a716541960,
title = "Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group",
abstract = "Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years. Indeed, an actual {"}epidemic{"} is expected in the next 20 years, with over 1300 new cases a y ear till 2020 at least. Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor. For all the above reasons, translational research is the key to success; indeed, ever increasing knowledge of the molecular mechanisms underlying MMe pathogenesis could lead (and is actually leading) to new, hopefully more active, treatment options. To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe). The aim of this report is to summarize the most significant advances in the different disciplines applied to MMe presented and discussed during the IMIG meeting and how these advances will be changing the perspective of patients with MMe.",
keywords = "GIMe, IMIG, Malignant mesothelioma",
author = "Camillo Porta and C. Porta and A. Ardizzoni and G. Gaudino and M. Maio and L. Mutti and C. Pinto and S. Porru and R. Puntoni and G. Tassi and M. Tognon",
year = "2005",
language = "English",
volume = "96",
pages = "360--369",
journal = "Medicina del Lavoro",
issn = "0025-7818",
publisher = "Mattioli 1885 S.p.A.",
number = "4",

}

TY - JOUR

T1 - Malignant mesothelioma in 2004

T2 - How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group

AU - Porta, Camillo

AU - Porta, C.

AU - Ardizzoni, A.

AU - Gaudino, G.

AU - Maio, M.

AU - Mutti, L.

AU - Pinto, C.

AU - Porru, S.

AU - Puntoni, R.

AU - Tassi, G.

AU - Tognon, M.

PY - 2005

Y1 - 2005

N2 - Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years. Indeed, an actual "epidemic" is expected in the next 20 years, with over 1300 new cases a y ear till 2020 at least. Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor. For all the above reasons, translational research is the key to success; indeed, ever increasing knowledge of the molecular mechanisms underlying MMe pathogenesis could lead (and is actually leading) to new, hopefully more active, treatment options. To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe). The aim of this report is to summarize the most significant advances in the different disciplines applied to MMe presented and discussed during the IMIG meeting and how these advances will be changing the perspective of patients with MMe.

AB - Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years. Indeed, an actual "epidemic" is expected in the next 20 years, with over 1300 new cases a y ear till 2020 at least. Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor. For all the above reasons, translational research is the key to success; indeed, ever increasing knowledge of the molecular mechanisms underlying MMe pathogenesis could lead (and is actually leading) to new, hopefully more active, treatment options. To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe). The aim of this report is to summarize the most significant advances in the different disciplines applied to MMe presented and discussed during the IMIG meeting and how these advances will be changing the perspective of patients with MMe.

KW - GIMe

KW - IMIG

KW - Malignant mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=33645074452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645074452&partnerID=8YFLogxK

M3 - Article

C2 - 16457433

AN - SCOPUS:33645074452

VL - 96

SP - 360

EP - 369

JO - Medicina del Lavoro

JF - Medicina del Lavoro

SN - 0025-7818

IS - 4

ER -